Recent Company News

• 07:07 AM ET Jun 09, 2026
  

  RedHill'announced that the FDA has granted rare pediatric disease (RPD) designation to opaganib for treatment of neuroblastoma (NB) ($1.02, 0.00)

• 07:01 AM ET Jun 09, 2026
  

  RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation

• 07:10 AM ET Jun 08, 2026
  

  RedHill launches enforcement of $11M New York Supreme Court final judgment against Kukbo ($1.03, 0.00)

• 07:01 AM ET Jun 08, 2026
  

  RedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against Kukbo

• 12:08 PM ET Jun 03, 2026
  

  RedHill Biopharma fournit une mise à jour concernant l’opaganib et Ebola ($1.01, 0.00)

• 12:08 PM ET Jun 03, 2026
  

  RedHill Biopharma provides update regarding opaganib and Ebola ($1.01, 0.00)

• 08:10 AM ET Jun 02, 2026
  

  RedHill Biopharma advancing opaganib options for novel dual host directed and direct acting antiviral approach for ebola outbreak biodefense platforms ($1.00, 0.00)

• 08:00 AM ET Jun 02, 2026
  

  RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms